期刊文献+

肝移植治疗门静脉高压上消化道出血的疗效分析 被引量:9

Analysis on Effect of Liver Transplantation in Treatment of Upper Gastrointestinal Hemorrhage in Patients with Portal Hypertension
原文传递
导出
摘要 目的探讨肝脏移植治疗门静脉高压症所致上消化道出血的可行性及安全性,并与传统手术的疗效进行比较。方法回顾性分析2009年2月至2012年2月期间浙江大学附属第一医院肝胆胰诊治中心收治的303例门静脉高压症合并上消化道出血患者的临床资料。其中101例患者接受肝移植治疗(肝移植组),202例患者接受常规手术治疗(常规手术组),术后随访8~44个月,平均26个月。结果常规手术组患者术前肝功能明显优于肝移植组(P<0.01),2组患者总体死亡率比较差异无统计学意义〔7.4%(14/189)比3.0%(3/101),P=1.00〕。肝移植组术后再出血率为2.0%(2/101),低于常规手术组的9.5%(18/189),P<0.05。肝移植组术后内镜下曲张静脉消失率为86.1%(87/101),高于常规手术组的54.5%(86/189),P<0.01。结论肝移植治疗门静脉高压症所致上消化道出血是安全可靠的。有出血史但术前肝功能尚好的患者,接受常规手术后能维持较好的肝脏功能和生活质量。终末期肝病门静脉高压症患者,肝移植是唯一的治愈方案。 Objective To explore the feasibility and safety of liver transplantation(LT) in treatment of upper gastrointestinal hemorrhage in patients with portal hypertension,and to compare the therapeutic effects with conventional operation(CO).Methods The clinical data of 303 patients with bleeding portal hypertension from Feb.2009 to Feb.2012 in the department of hepatobiliary and pancreatic surgery of First Affiliated Hospital of Zhejiang University were retrospectively analyzed.One hundred and one patients received LT procedure(LT group),whereas the other 202 patients received CO procedure(CO group).Postoperative follow-up period was 8-44 months(average 26 months).Results Liver function before operation in CO group was significantly better than that in LT group (P0.01).The mortality of CO group and LT group were 7.4% (14/189) and 3.0% (3/101,P=1.00),respectively.The rebleeding rate of patients underwent LT was 2.0% (2/101),significantly lower than that of CO group(9.5% (18/189),P0.05).The vanish rate of esophagogastric varice in patients underwent LT was 86.1% (87/101),significantly lower than that of CO group(54.5% (86/189),P0.01).Conclusions LT treatment for bleeding portal hypertension is feasible and safe.Patients with good liver function despite hemorrhage history may be managed satisfactorily with conventional surgery.LT is the only curative treatment for patients with portal hypertension in end-stage liver disease.
出处 《中国普外基础与临床杂志》 CAS 2013年第1期24-28,共5页 Chinese Journal of Bases and Clinics In General Surgery
基金 卫生行业科研专项项目基金(项目编号:201002015)~~
关键词 肝移植 门静脉高压症 上消化道出血 Liver transplantation Portal hypertension Upper gastrointestinal hemorrhage
  • 相关文献

参考文献3

二级参考文献70

  • 1Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R. B-blockers to prevent gastroesopha- geal varices in patients with cirrhosis. N Engl ] Med 2005; 353:2254-2261.
  • 2Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J. Hepatic venous pressure gradient pre- dicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133:481-488.
  • 3Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, Bru C, Rod6s J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preop- erative portal pressure. Gastroenteroloxy 1996; 111:1018-1022.
  • 4Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50: 923-928.
  • 5de Franchis R, Pascal JP, Ancona E, Burroughs AK, Hen- derson M, Fleig W, Groszmann R, Bosch J, Sauerbruch T, Soederlund C. Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. ] Hepato11992; 15:256-261.
  • 6de Franchis R. Developing consensus in portal hypertension. J Hepato11996; 25:390-394.
  • 7Laine L, Cook D. Endoscopic ligation compared with sclero- therapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123:280-287.
  • 8Grace NI, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makuch RW, Bosch J, Stiegmann GV, Henderson JM, de Franchis R, Wagner JL, Conn HO, Rodes J. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998; 28:868-880.
  • 9Levacher S, Letoumelin P, Pateron D Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346:865-868.
  • 10de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions,methodology and therapeutic strategies in portal hyperten- sion. J Hepato12000; 33:846-852.

共引文献58

同被引文献117

引证文献9

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部